Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

[Articles] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

20:41 EDT 27 Jun 2013 | The Lancet

A recommended phase 2 dose of 300 mg/day niraparib is well tolerated. Niraparib should be further assessed in inherited and sporadic cancers with homologous recombination DNA repair defects and to target PARP-mediated transcription in cancer.

Original Article: [Articles] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

NEXT ARTICLE

More From BioPortfolio on "[Articles] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial"

Search BioPortfolio:
Advertisement

Relevant Topic

Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs.  Cancer sometimes begins in one part of the body before spre...

Advertisement

Searches Linking to this Story